Malignant neoplasms of prostate ICD11 code: 2D32.Z
Parenteral > General injections > IM: 7.5 mg in prefilled syringe ; 22.5 mg in prefilled syringe
EML status history
Adolescents and adults
Medicines within the same pharmacological class can be used
Patents have expired in most jurisdictions
Read more about patents.
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, leuprorelin (with a square box) was added to the complementary list of the EML for use in the treatment of metastatic prostate cancer. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for metastatic prostate cancer is attached.